Use of oxytocin for the preparation of a pharmaceutical composition against cancer in situ and cervicitis

Pharmaceutical composition against cancer in situ and cervicitis, characterised in that it comprises an effective concentration of at least one substance oxytocin activity in mixture or otherwise together with at least one pharmaceutically acceptable carrier or excipient, wherein the substance is selected from the group consisting of the following compounds:

• 31
• wherein
• X1 is selected from the group consisting of Cys, Mpa and nothing,
• X2 is selected from the group consisting of Tyr, (O-methyl-Tyr), Phe, and nothing,
• X3 is selected from the group consisting of Ile, Val, Hoph, Phe, Cha, and nothing,
• X4 is selected from the group consisting of Gln, Ser, Thr, Cit, Arg, and Daba,
• X5 is selected from the group consisting of Pro, and nothing,
• X6 is selected from the group consisting of Ile, Leu, nothing, Val, Hos, Daba, Thr, Arg, and Cit,
• X7 is selected from the group consisting of Gly, nothing, and Ala,
• X8 is selected from the group consisting of Gly, and nothing,
• X9 is selected from the group consisting of CH2 and S;
• as well as salts thereof.

Compound of the formula (I):

• 32
• wherein
• either:
• X1 is Cys, X2 is Tyr, X3 is Ile, X4 is Gln, X5-X8 is nothing, and X9 is S;
• or
• X1 is nothing, X2 is Tyr, X3 is Ile, X4 is Gln, X5 is Pro, X6 is Leu, X7 is Gly, X8 is nothing, and X9 is S;
• or
• X1-X2 is nothing, X3 is Ile, X4 is Gln, X5 is Pro, X6 is Leu, X7 is Gly, X8 is nothing, and X9 is S;
• or
• X1-X3 is nothing, X4 is Gln, X5 is Pro, X6 is Leu, X7 is Leu, X8 is nothing, and X9 is S;
• or
• X1-X2 is nothing, X3 is Ile, X4 is Gln, X5 is Pro, X6-X9 is nothing, and X9 is S;
• as well as salts thereof.